Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04626895 · ClinicalTrials.gov registry record · NA

Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers

A NA study, sponsored by Medstar Health Research Institute.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT04626895 is a NA study that has completed, run by Medstar Health Research Institute. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04626895, a NA study, has completed, sponsored by Medstar Health Research Institute.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

This study will measure the efficacy of scalp cooling with the Paxman Scalp Cooling (PSC) device in a diverse patient population with success measured as prevention of more than 50% hair loss during chemotherapy. We propose that scalp cooling has distinct efficacy in participants with black or ethnic-minority hair types due to differences in textures, hair thickness. This study will examine the success rate of scalp cooling in black patients receiving chemotherapy for breast or gynecological cancer.

Interventions

  • DEVICE Paxman Scalp Cooling Device

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-06-04
Est. Completion 2020-10-01
Phase NA

Sponsor

Medstar Health Research Institute

115 total trials

What the Registry Record Tells You About NCT04626895

The ClinicalTrials.gov registry entry for NCT04626895 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Paxman Scalp Cooling Device is the first listed.

NCT04626895 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04626895 about?

NCT04626895 is a clinical study titled "Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers". This study will measure the efficacy of scalp cooling with the Paxman Scalp Cooling (PSC) device in a diverse patient population with success measured as prevention of more than 50% hair loss during chemotherapy. We propose that scalp cooling has distinct efficacy in participants with black or ethni...

What is the current status of trial NCT04626895?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2019-06-04. Estimated completion is 2020-10-01.

What interventions are being tested in trial NCT04626895?

The interventions under investigation include: Paxman Scalp Cooling Device (DEVICE).

Who is sponsoring clinical trial NCT04626895?

This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.